AdaptHealth (AHCO) Q1 2026 Earnings Transcript

AdaptHealth reported Q1 revenue of $819.8 million, up 5.4% year over year and about $22 million above the guidance midpoint, while lifting full-year revenue guidance by $10 million to $3.45 billion-$3.52 billion. Adjusted EBITDA came in at $121.2 million, about $7 million below expectations due to $12 million of elevated labor costs tied to the capitated-contract transition, but management said those costs should normalize by Q3. The company also completed a $1.1 billion refinancing, expanded its capitated contract to about 15 million covered lives, and said AI-enabled scheduling is now 25% touchless.

Analysis

AHCO just proved the business is no longer a simple reimbursement lever; it is becoming a platform play with capitation as the swing factor. The near-term margin miss is mostly transition noise, but the important second-order effect is that the new contract front-loads fixed-cost absorption while de-risking future pricing power if management can keep utilization and product costs in line. That creates a stronger 2027 setup than the reported quarter suggests, because the incremental margin on a fully ramped capitated book should fall through faster than the base business.

The competitive implications are meaningful: scaled operators with national footprint, compliance infrastructure, and de novo execution capability should take share from smaller HME providers that cannot fund transition capex or labor duplication. The refinancing also matters beyond optics — lower debt cost and longer maturities reduce the probability that AHCO is forced into suboptimal asset sales or a liquidity-driven slowdown just as the contract pipeline opens up. The biggest beneficiary of this cycle may be not just AHCO, but any balance-sheet-clean peer that can win similar deals without the same upfront cash drain.

The market is likely underappreciating how quickly the operational bridge can close once onboarding rolls off. The key catalyst window is Q2 to Q3: if labor normalization and capex moderation show up on schedule, EBITDA and FCF should inflect sharply, turning the current leverage concern into an argument for multiple expansion. The main tail risk is execution slippage — if additional capitation wins arrive before the first deal is fully stabilized, AHCO could re-enter a high-burn, high-complexity phase and the stock will likely punish any evidence that capex or labor remain sticky.

Contrarian view: consensus may be too focused on the headline leverage ratio and too dismissive of the quality of the revenue stream being added. If management can repeatedly convert these contracts at ~20% EBITDA margins and keep base business growth in the high-single digits, the stock should trade less like a low-margin DME supplier and more like an infrastructure-style compounder with recurring contracting power. The market is giving credit for neither the pipeline nor the operating leverage from digital scheduling and patient self-service, which are still early but could become meaningful in 2027.

Key Decisions for Investors

• Long AHCO for a 3-6 month trade into Q3 normalization; upside comes from EBITDA/FCF inflection if labor and capex roll off as guided, with downside capped by the refinancing and extension of maturities.
• Buy AHCO January 2027 calls or call spreads to express the 2027 operating leverage story; this limits carry while capturing the rerating if capitation scales and margins move toward the low-20s.
• Pair trade: long AHCO / short a smaller HME or post-acute operator with weaker scale and higher leverage; the relative thesis is that capitation and compliance favor national platforms and widen the moat.
• If already long AHCO, sell out-of-the-money puts on any post-earnings pullback only if Q2 guidance hold is credible; implied vol should remain elevated while the market digests capex and leverage, creating attractive premium.
• Avoid shorting AHCO on the leverage headline alone; a cleaner expression of the bear case is shorting into any failed Q2 execution or delayed margin recovery, because the stock’s real risk is operational slippage, not current debt level.